Search results
Remediation Forest coming to East Canfield Art Park in Detroit
Detroit Free Press· 6 days agoOver the next two years, the East Canfield Art Park will be transformed into an inner-city forest,...
AstraZeneca to present respiratory disease research at ATS 2024 By Investing.com
Investing.com· 4 days agoAstraZeneca (NASDAQ:AZN) is set to present new clinical and real-world data on its respiratory and...
What to Know About Steroids for Treating Back Pain
Healthline· 2 days agoSteroids help reduce inflammation that can cause severe back pain, but steroids aren’t long-term solutions. Back pain can limit your mobility and...
Foresee Pharmaceuticals Announces Poster Presentation and Participation at the 2024 American...
WTNH-TV New Haven· 6 days ago... of aderamastat (FP-025), A Selective MMP-12 Inhibitor, on Allergen-induced Airway Responses in...
Newly approved medication gives hope to patients dealing with severe allergies
WTSP-TV Tampa· 2 days agoIn November, the Alabsi family went to spend a family fun day at the zoo in Tampa. The day ended in...
AJRCCM “Abstracts Issue” Showcases Research at the ATS 2024 International Conference
Newswise· 4 days agoMay 01, 2024– Get a sneak-peak at what’s coming up at the ATS 2024 later this month with today’s online release of the “American Thoracic Society International Conference Abstracts.” Published ...
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Zacks· 2 days agoFree Report) reported first-quarter 2024 adjusted earnings of $3.96 per share, which beat the Zacks Consensus Estimate of $3.76. Total revenues of $7.45 billion beat the Zacks Consensus Estimate ...
An effective treatment for COVID-19 is underused - The Advocate-Messenger
The Danville Advocate-Messenger· 3 days agoA safe and effective medication designed to prevent mild-to-moderate COVID-19 infections from...
AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Fontana Herald News· 2 days agoAmgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024. "With many of our innovative products delivering strong growth and promising new medicines advancing through ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 3 days agoPDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024